Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJFS5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,747
Award facts
- Contract value 100% obligated
- $1,747.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml autoinjector. The delivery order, issued on December 22, 2025, with an ultimate completion date of January 14, 2026, represents a firm fixed-price procurement with no set-aside designation, indicating the vendor competed in an unrestricted federal procurement environment. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion master contract awarded November 13, 2025, that establishes the company as a regional prime vendor contractor for pharmaceutical supplies supporting Department of Defense healthcare operations globally.
DMS Pharmaceutical Group's Xolair supply falls within the broader scope of the PPV-G GEN V acquisition strategy, a $30.3 billion government-wide initiative designed to streamline pharmaceutical procurement for military medical facilities worldwide. The company's established performance across numerous delivery orders spanning diverse therapeutic categories—from oncology treatments to biologics and specialty pharmaceuticals—demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system. As a critical supplier within the federal pharmaceutical supply chain since 2001, DMS Pharmaceutical Group leverages its small business status and extensive product portfolio to provide consistent, competitive procurement solutions to the Department of Defense.
Quick answers
Who was awarded contract SPE2DR26FJFS5?
SPE2DR26FJFS5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FJFS5 worth?
The government has obligated $1,747 on SPE2DR26FJFS5.
Is contract SPE2DR26FJFS5 an order under another contract?
Yes. SPE2DR26FJFS5 is a delivery order under SPE2DR25D9157, an indefinite delivery contract.
Was contract SPE2DR26FJFS5 competed?
The extent of competition for SPE2DR26FJFS5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award